Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIT-001 for Prevention of Oral Mucositis in HSCT (Capella)
NCT05493800Phase 2Active, not recruiting
- Sponsor
- MitoImmune Therapeutics
- Start
- Feb 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LC28-0126 in oral mucositis (OM) (6 arms), sponsored by MitoImmune Therapeutics. Primary endpoint: Incidence of Severe Oral Mucositis (SOM). Started Feb 2022; status: active, not recruiting.
02
Drugs
LC28-0126
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT05493800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493800.